Document 1083
 DOCN  M9471083
 TI    Results in adults with small noncleaved cell (SNCL) lymphoma treated
       with a short duration. Intensive chemotherapy protocol also used in
       pediatric patients (Meeting abstract).
 DT    9409
 AU    Magrath IT; Adde M; Shad A; Wittes RE; Horak ID; NCI, Bethesda, MD
 SO    Proc Annu Meet Am Soc Clin Oncol; 13:A1252 1994. Unique Identifier :
       AIDSLINE ICDB/94601248
 AB    We have treated 20 adult patients with SNCL (12 BL, 7 non-BL, and 1
       indeterminate) with an intensive chemotherapy protocol. None of the
       patients were infected with HIV. The protocol consisted of two regimens,
       A and B. Regimen A included CTX, ADR, VCR, and high dose MTX, and
       regimens B: IFOS, VP16 and high dose Ara-C. Two (alternating) cycles of
       each regimen were given to high risk patients (15), and 3 cycles of
       regimen A to low risk patients (5). Each cycle commenced as soon as
       granulocytes recovered to 1000 per cu mm. The total duration of therapy
       was 12-16 wk for high risk patients and 9-12 wk for low risk patients.
       All patients received IT Ara-C and MTX. 6 patients were Stage I, 11
       Stage III and 3 Stage IV according to the St. Jude classification used
       for pediatric SNCL. The age range was 18 to 59 years (median, 25 years).
       Low risk patients had a single extra-abdominal mass and an LDH less than
       350. All other patients were considered high risk (mean LDH 954 iu/l). 5
       patients are too early to evaluate at this time (less than 6 mo from the
       start of therapy). All 15 evaluable patients achieved CR and remain in
       CR with a median follow up of 24 mo (range 6-51 mo). Most patients are
       already beyond the high risk period for relapse (within 10 months from
       the start of treatment). Toxicity was no worse in adults than in
       children; the durations of myelosuppression, incidence of sepsis and
       mucositis were similar, although adults appeared to develop neuropathy
       more often. The preliminary results of this study are excellent, even in
       very high risk patients, and suggest that adults with SNCL have a
       similar prognosis to children when treated with an appropriate,
       intensive chemotherapy regimen.
 DE    Adolescence  Adult  Antineoplastic Agents, Combined/ADVERSE
       EFFECTS/*THERAPEUTIC USE  Dose-Response Relationship, Drug  Drug
       Administration Schedule  Female  Follow-Up Studies  Human  Lymphoma,
       Small Noncleaved-Cell/MORTALITY/PATHOLOGY/*THERAPY  Male  Middle Age
       Neoplasm Staging  Survival Rate  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).